To date, two highly potent RET-specific TKIs, selpercatinib and pralsetinib, have been approved by the US Food and Drug Administration (FDA) for the treatment of advanced or metastatic RET-altered NSCLC and thyroid cancers. Here, RET is linked to thyroid gland carcinoma.